The putative use of lithium in alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 8, 2016, Pages 853-861

  Morris, Gerwyn ^a   Berk, Michael ^b,c  

^a Tir Na Nog   (United Kingdom)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer s disease; Amyloid; Beta tau; Calcium; Dementia; Inflammation; Iron; Lithium; Microglia; Mitochondria; Oxidative stress; Phosphorylation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CALCIUM; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; LITHIUM; PROTEASOME; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; UBIQUITIN; LITHIUM DERIVATIVE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ASTROCYTE; AUTOPHAGY; CALCIUM HOMEOSTASIS; CELL ACTIVATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; EXCITOTOXICITY; HUMAN; INFLAMMATION; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; UBIQUITIN PROTEASOME SYSTEM; ANIMAL; BRAIN; DRUG EFFECTS; IMMUNOLOGY; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; LITHIUM COMPOUNDS; NEUROPROTECTIVE AGENTS;

EID: 84975763705     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160219113112     Document Type: Article

References (141)

1. McCord MC, Aizenman E. The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease. Front Aging Neurosci 6: 77 (2014).
2. Poalelungi A, Popescu BO. Alzheimer’s disease: psychiatric or neurological disorder? Romanian J Neurol 12: 5-14 (2013).
3. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 275: 251-283 (2014).
4. Llorens-Martin M, Jurado J, Hernandez F, Avila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 7: 46 (2014).
5. Hayden EY, Teplow DB. Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res Ther 5: 60 (2013).
6. Becker RE, Greig NH, Giacobini E, Schneider LS, Ferrucci L. A new roadmap for drug development for Alzheimer's disease. Nat Rev Drug Discov 13: 156 (2014).
7. Lansdall C. An effective treatment for Alzheimer's disease must consider both amyloid and tau. Biosci Horizons 7: hzu002-hzu002 (2014).
8. Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J Alzheimers Dis 33: S141-S144 (2013).
9. Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacol 35: 1761-1774 (2010).
10. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 61: 216-222 (2007).
11. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord 12: 87-94 (2010).
12. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 10: 104-107 (2013).
13. Close H, Reilly J, Mason J, Kripalani M, Wilson D, Main J, et al. Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PloS One 9: e90169 (2014).
14. Lustbader J. ABAD directly links abeta to mitochondrial toxicity in Alzheimer's disease. Science 304: 448-452 (2004).
15. Takuma K. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19: 597-598 (2005).
16. Resende R, Moreira P, Proenca T, Deshpande A, Busciglio J, Pereira C, et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med 44: 2051-2057 (2008).
17. Ferrer I. Altered mitochondria, energy metabolism, voltagedependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer’s disease. J Bioenerg Biomembr 41: 425-431 (2009).
18. Fernandez-Echevarria C, Diaz M, Ferrer I, Canerina-Amaro A, Marin R. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer’s disease. Neuroscience 278: 354-366 (2014).
19. Kawahara M. Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. Curr Pharm Des 16: 2779-2789 (2010).
20. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life 60: 575-590 (2008).
21. Kawahara M, Negishi-Kato M, Sadakane Y. Calcium dyshomeostasis and neurotoxicity of Alzheimer’s beta-amyloid protein. Exp Rev Neurother 9: 681-693 (2009).
22. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 11: 1193-1206 (2010).
23. Chang S, Ma T, Miranda R, Balestra M, Mahley R, Huang Y. Lipid-and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci USA 102: 18694-18699 (2005).
24. Moreira P, Cardoso S, Santos M, Oliveria C. The key role of mitochondria in Alzheimer's disease. J Alzheimers Dis 9: 101-110 (2006).
25. Armstrong R. Review paper A critical analysis of the ‘amyloid cascade hypothesis’. Folia Neuropathol 52: 211-225 (2014).
26. Chen L, Na R, Gu M, Richardson A, Ran Q. Lipid peroxidation upregulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer’s disease. J Neurochem 107: 197-207 (2008).
27. Quiroz-Baez R, Rojas E, Arias C. Oxidative stress promotes JNKdependent amyloidogenic processing of normally expressed human APP by differential modification of alpha-, beta-and gamma-secretase expression. Neurochem Int 55: 662-670 (2009).
28. Sambamurti K. Gene structure and organization of the human betasecretase (BACE) promoter. FASEB J 18: 1034-1036 (2004).
29. Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch M, et al. Expression of APP pathway mRNAs and proteins in Alzheimer’s disease. Brain Res 1161: 116-123 (2007).
30. Zhu X, Raina A, Rottkamp C, Boux H, Siedlak S, Takeda A, et al. Activation of P38 kinase links π phosphorylation, oxidative stress and cell cycle-related events in Alzheimer disease. Neurobiol Aging 21: 267 (2000).
31. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/ chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 29: 19-36 (2014).
32. Kenche V, Barnham K. Alzheimer's disease & metals: therapeutic opportunities. B J Pharmacol 163: 211-219 (2011).
33. Greenough M, Camakaris J, Bush A. Metal dyshomeostasis and oxidative stress in Alzheimer’s disease. Neurochem Int 62: 540-555 (2013).
34. Borchardt T, Camakaris J, Cappai R, Masters CL, Beyreuther K, Multhaup G. Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J 344: 461-467 (1999).
35. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802: 2-10 (2010).
36. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta 1842: 1240-1247 (2014).
37. Zhu X, Perry G, Moreira P, Aliev G, Cash A, Hirai K, et al. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. J Alzheimers Dis 9: 147-153 (2006).
38. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader J, et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19: 2040-2041 (2005).
39. Eckert A, Schmitt K, Gotz J. Mitochondrial dysfunction-the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimers Res Ther 3: 15 (2011).
40. Swerdlow R, Khan S. The Alzheimer's disease mitochondrial cascade hypothesis: An update. Exp Neurol 218: 308-315 (2009).
41. Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G. Clinical features and pathogenesis of Alzheimer's disease: involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol 685: 34-44 (2010).
42. Albrekkan FM, Kelly-Worden M. Mitochondrial dysfunction and Alzheimer’s disease. OJEMD 3: 14-19 (2013).
43. Gee J, Keller J. Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int J Biochem Cell Biol 37: 1145-1150 (2005).
44. Rodriguez J, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death Diff 16: 378-385 (2009).
45. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485: 512-516 (2012)
46. Dal Pra I, Chiarini A, Pacchiana R, Gardenal E, Chakravarthy B, Whitfield JF, et al. Calcium-sensing receptors of human astrocyteneuron teams: amyloid-β-driven mediators and therapeutic targets of Alzheimer's disease. Curr Neuropharmacol 12: 353-364 (2014).
47. Doens D, Fernandez P. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflamm 11: 48 (2014).
48. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 61: 71-90 (2013).
49. Boutajangout A, Wisniewski T. The innate immune system in Alzheimer’s disease. Intern J Cell Biol 2013: 1-7 (2013).
50. Lue L, Schmitz C, Sorrano G, Sue L, Beach T, Walker D. TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in postmortem temporal cortices. Brain Pathol 25(4): 469-480 (2015).
51. Hickman S, El Khoury J. TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 88: 495-498 (2014).
52. Liu S, Liu Y, Hao W, Wolf L, Kiliaan A, Penke B. et al. TLR2 Is a primary receptor for Alzheimer's amyloid β peptide to trigger neuroinflammatory Activation. J Immunol 188: 1098-1107 (2011).
53. Doens D, Fernandez P. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J Neuroinflamm 11: 48 (2014).
54. Lukiw W. Antagonism of NF-κ B-up-regulated micro RNAs (miRNAs) in sporadic Alzheimer's disease (AD) anti-NF-κB vs. anti-miRNA strategies. Front Genet 4: 77 (2013).
55. Rubio-Perez J, Morillas-Ruiz J. A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci World J 2012: 1-15 (2012).
56. Politis A, Olgiati P, Malitas P, Albani D, Signorini A, Polito L, et al. Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. J Alzheimers Dis 19: 481-488 (2010).
57. Lovestone S, Simmons A. Combinatorial markers of MCI conversion: Cytokines and MRI measures together predict disease progression. Alzheimer's Dement 6: S62 (2010).
58. Upadhya SC, Hegde AN. Role of the ubiquitin proteasome system in Alzheimer's disease. BMC Biochem 8: S12 (2007)
59. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 12: 363-373 (2008).
60. Cecarini V, Ding Q, Keller JN. Oxidative inactivation of the proteasome in Alzheimer's disease. Free Radic Res 41: 673-680 (2007).
61. Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 59: 952-962 (2006).
62. Friguet B, Szweda LI. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett 405: 21-25 (1997).
63. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274: 23787-23793 (1999).
64. Catalgol B, Grune T. Protein pool maintenance during oxidative stress. Curr Pharm Des 15: 3043-3051 (2009).
65. Saido T, Leissring MA. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med 2: a006379 (2012).
66. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy--a novel Beta-amyloid peptidegenerating pathway activated in Alzheimer's disease. J Cell Biol 171: 87-98 (2005).
67. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci 28: 6926-6937 (2008).
68. Ułamek-Kozioł M, Furmaga-Jabłońska W, Januszewski S, Brzozowska J, Sciślewska M, Jabłoński M, et al. Neuronal autophagy: self-eating or self-cannibalism in Alzheimer's disease. Neurochem Res 38: 1769-1773 (2013).
69. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 118: 777-788 (2008).
70. Zhang L, Sun Y, Fei M, Tan C, Wu J, Zheng J, et al. Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization. Autophagy 10: 1015-1035 (2014).
71. Pivtoraiko VN, Stone SL, Roth KA, Shacka JJ. Oxidative stress and autophagy in the regulation of lysosome-dependent neuron death. Antioxid Redox Signal 11: 481-496 (2009).
72. Ditaranto K, Tekirian TL, Yang AJ. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol Dis 8: 19-31 (2001).
73. Ullrich C, Mlekusch R, Kuschnig A, Marksteiner J, Humpel C. Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. Curr Alzheimer Res 7: 549-555 (2010).
74. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101: 2173-2178 (2004).
75. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K, Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56: 70-78 (1997).
76. Mateo I, Infante J, Llorca J, Rodriguez E, Berciano J, Combarros O. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 21: 228-232 (2006).
77. Cho JH, Johnson GV. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88: 349-358 (2004).
78. Asuni AA, Hooper C, Reynolds CH, Lovestone S, Anderton BH, Killick R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci 24: 3387-3392 (2006).
79. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, et al. Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321: 61-64 (2002).
80. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, Frangione B. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 12: 343-357 (2002).
81. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439 (2003).
82. Zhang H, Ma Q, Zhang Y, Xu H. Proteolytic processing of Alzheimer’s beta-amyloid precursor protein. J Neurochem 120:9-21 (2012).
83. Cai Z, Yan LJ. Rapamycin, autophagy, and Alzheimer's disease. J Biochem Pharmacol Res 1: 84-90 (2013).
84. Deng Y, Xiong Z, Chen P, Wei J, Chen S, Yan Z. β-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3. Neurobiol Aging 35: 449-459 (2014).
85. Green HF, Nolan YM. GSK-3 mediates the release of IL-1β, TNF-α and IL-10 from cortical glia. Neurochem Int 61: 666-671 (2012).
86. Koriyama Y, Nakayama Y, Matsugo S, Sugitani K, Ogai K, Takadera T, Kato S. Anti-inflammatory effects of lipoic acid through inhibition of GSK-3β in lipopolysaccharide-induced BV-2 microglial cells. Neurosci Res 77: 87-96 (2013).
87. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535-1549 (2004).
88. Mines M, Beurel E, Jope R. Regulation of cell survival mechanisms in Alzheimer's disease by glycogen synthase kinase-3. Int J Alzheimers Dis 2011: 1-11 (2011).
89. King T, Clodfelder-Miller B, Barksdale K, Bijur G. Unregulated mitochondrial GSKbeta activity results in NADH: Ubiquinone oxidoreductase deficiency. Neurotox Res 14: 367-382 (2008).
90. Fu ZQ, Yang Y, Song J, Jiang Q, Lin ZC, Wang Q, et al. LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3β in vivo and in vitro. J Alzheimers Dis 21: 1107-1117 (2010).
91. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, et al. Lithium, a common drug for bipolar disorder treatment, regulates amyloidbeta precursor protein processing. Biochemistry 43: 6899-6908 (2004).
92. Yu F, Zhang Y, Chuang DM. Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 29: 2342-2351 (2012).
93. Zhang H, Ma Q, Zhang Y, Xu H. Proteolytic processing of Alzheimer’s beta-amyloid precursor protein. J Neurochem 120: 9-21 (2012).
94. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Lithium protects cultured neurons against betaamyloid-induced neurodegeneration. FEBS Lett 453: 260-264 (1999).
95. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 4: 153-165 (2002).
96. Chen CL, Lin CF, Chiang CW, Jan MS, Lin YS. Lithium inhibits ceramide-and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol Pharmacol 70: 510-517 (2006).
97. Ghribi O, Herman MM, Spaulding NK, Savory J. Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. J Neurochem 82: 137-145 (2002).
98. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104: 1433-1439 (2008).
99. Shim SS, Hammonds MD, Ganocy SJ, Calabrese JR. Effects of sub-chronic lithium treatment on synaptic plasticity in the dentate gyrus of rat hippocampal slices. Prog Neuropsychopharmacol Biol Psychiatry 31: 343-347 (2007).
100. Voytovych H, Krivanekova L, Ziemann U. Lithium: a switch from LTD-to LTP-like plasticity in human cortex. Neuropharmacology 63: 274-279 (2012).
101. Gao Y, Romero-Aleshire MJ, Cai Q, Price TJ, Brooks HL. Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of renal collecting duct cells. Am J Physiol Renal Physiol 305: F1201-F1208 (2013).
102. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33: 67-75 (2010).
103. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci 25: 11300-11312 (2005).
104. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, et al. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One 5: pii: e12845 (2010).
105. Xia Y, Wang C, Liu J, Anastasio N, Johnson K. Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role PI-3K/Akt and MEK/ERK signaling pathways. J Pharmacol Exp Ther 326: 838-848 (2008).
106. Xu J, Culman J, Blume A, Brecht S, Gohlke P. Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 34: 1287-1292 (2003).
107. Crespo-Biel N, Camins A, Pallas M, Canudas A. Evidence of calpain/ cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 56: 422-428 (2009).
108. Motoi Y, Shimada K, Ishiguro K, Hattori N. Lithium and autophagy. ACS Chem Neurosci 5(6): 734-742 (2014).
109. Underwood B. Understanding the neuroprotective mechanisms of lithium may have clinical significance. Br J Psychiatry 199: 166-167 (2011).
110. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 170: 1101-1111 (2005).
111. Sofola-Adesakin O, Castillo-Quan JI, Rallis C, Tain LS, Bjedov I, Rogers I, et al. Lithium suppresses Aβ pathology by inhibiting translation in an adult Drosophila model of Alzheimer's disease. Front Aging Neurosci 6: 190 (2014).
112. Jing P, Zhang JY, Ouyang Q, Wu J, Zhang XJ. Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3β. Chem Biol Interact 203: 309-313 (2013).
113. Maurer I, Schippel P, Volz H. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 11: 515-522 (2009).
114. Bachmann R, Wang Y, Yuan P, Zhou R, Li X, Alesci S, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 12: 805-822 (2009).
115. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65: 10545-10554 (2005).
116. Cunningham J, Rodgers J, Arlow D, Vazquez F, Mootha V, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 450: 736-740 (2007).
117. Ramanathan A, Schreiber SL. Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci USA 106: 22229-22232 (2009).
118. Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33: 67-75 (2010).
119. Shalbuyeva N, Brustovetsky T, Brustovetsky N. Lithium desensitizes brain mitochondria to calcium, antagonizes permeability transition, and diminishes cytochrome C release. J Biol Chem 282: 18057-18068 (2007).
120. Plotnikov EY, Kazachenko AV, Vyssokikh MY, Vasileva AK, Tcvirkun DV, Isaev NK, et al. The role of mitochondria in oxidative and nitrosative stress during ischemia/reperfusion in the rat kidney. Kidney Int 72: 1493-1502 (2007).
121. Bush AL, Hyson RL. Lithium increases bcl-2 expression in chick cochlear nucleus and protects against deafferentation-induced cell death. Neuroscience 138: 1341-1349 (2006).
122. Ghribi O, Herman MM, Spaulding NK, Savory J. Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. J Neurochem 82: 137-145 (2002).
123. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326 (1998).
124. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 12: 805-822 (2009).
125. Nahman S, Belmaker RH, Azab AN. Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. Innate Immun 18: 447-458 (2012).
126. Li H, Li Q, Du X, Sun Y, Wang X, Kroemer G, et al. Lithiummediated long-term neuroprotection in neonatal rat hypoxiaischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. J Cereb Blood Flow Metab 31: 2106-2115 (2011).
127. Basselin M, Villacreses NE, Lee HJ, Bell JM, Rapoport SI. Chronic lithium administration attenuates up-regulated brain arachidonic acid metabolism in a rat model of neuroinflammation. J Neurochem 102: 761-772 (2007).
128. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32: 577-595 (2007).
129. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptormediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6: 777-784 (2005).
130. Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26: 5083-5090 (2006).
131. Yuskaitis CJ, Jope RS. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal 21: 264-273 (2009).
132. Cortes-Vieyra R, Bravo-Patino A, Valdez-Alarcon JJ, Juarez MC, Finlay BB, Baizabal-Aguirre VM. Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens. J Inflamm (Lond). 9: 23 (2012).
133. Guloksuz S, Altinbas K, Aktas Cetin E, Kenis G, Bilgic Gazioglu S, Deniz G, et al. Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord 143: 148-152 (2012).
134. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang D. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43: 1173-1179 (2002).
135. Machado-Vieira R, Manji HK, Jr. Zarate CA.The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 11: 92-109 (2009).
136. Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 13: 617-622 (2010).
137. Nonaka S, Hough C, Chuang D. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 95: 2642-2647 (1998).
138. Chalecka-Franaszek E, Chuang D. Lithium activates the serine/ threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 96: 8745-8750 (1999).
139. Aliyazicioglu R, Kural B, Colak M, Karahan SC, Ayvaz S, Deger O. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. Tohoku J Exp Med 213: 79-87 (2007).
140. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Jr. Cereser V, da Silva Vargas R, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421: 33-36 (2007).
141. Khairova R, Pawar R, Salvadore G, Juruena MF, de Sousa RT, Soeiro-de-Souza MG, et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep 5: 680-682 (2012).